Compare Eli Lilly And Co (LLY) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Trade Desk Inc — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Trade Desk Inc trades at $12.1 (market cap $5.83B). The key difference: Eli Lilly And Co is far larger — about 178.4× Trade Desk Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Trade Desk Inc for 72 Days on average.
| LLY | TTD | |
|---|---|---|
Market Cap | $1.04T | $5.83B |
Volume | 3,064,878 | 15,864,392 |
Sector | Health | Media |
52-Week High | $1.28K | $54.13 |
52-Week Low | $799.57 | $11.92 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $1.09T | $4.78B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
The Trade Desk (TTD) trades at $12.08, down 0.08% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $2.90B and net income of $443.30M, though 2026 guidance indicates slowing growth. Valuation metrics appear attractive with P/E of 0.15 and P/S of 0.02. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions.
Investment outlook remains cautious despite attractive valuations. The stock faces headwinds from slowing revenue growth and intense competition, but maintains leadership in programmatic advertising. Analyst consensus suggests 22% upside to $14.72 target, though mixed ratings reflect uncertainty about near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
